P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)

• L. J. Nastoupil,
• S. O’Brien,
• H. E. Holmes,
• L. Dsouza,
• D. Hart,
• E. Matsuda,
• T. Satterfield-Ledbetter,
• J. Skoble,
• E. Garner,
• M. Bryan,
• S. Kanner,
• E. Li,
• C. T. Thomas,
• J. Essell

Affiliations

L. J. Nastoupil

1 Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston

S. O’Brien

2 Department of Hematology and Oncology, University of California Irvine, Irvine

H. E. Holmes

3 Oncology, Texas Oncology/Baylor Sammons Cancer Center, Dallas

L. Dsouza

1 Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston

D. Hart

4 Research, Oncology Hematology Care, Cincinnati

E. Matsuda

5 UCI Cancer Center, University of California Irvine, Irvine

T. Satterfield-Ledbetter

6 Clinical Oncology Research Coordination, Baylor Research Institution, Dallas

J. Skoble

7 Technical Operations

E. Garner

8 T Cell Therapeutics

M. Bryan

9 Program Management/Operations

S. Kanner

10 R&D, Caribou Biosciences, Inc., Berkeley

E. Li

11 EffectStats LLC, Cambridge

C. T. Thomas

12 Clinical Development, Caribou Biosciences, Inc., Berkeley

J. Essell

13 Blood Cancer, Oncology Hematology Care, Cincinnati, United States of America